Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen

Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, HER2 overexpressing breast cancer cells respond poorly to tamoxifen therapy presumably by pass. The molecular mechanisms underlying development of tamoxifen resistance have not been well established. Rec...

Full description

Saved in:
Bibliographic Details
Published in:Am J Cancer Res
Main Authors: Yin, Li, Pan, Xiaohua, Zhang, Xin-Tian, Guo, Yu-Ming, Wang, Zhao-Yi, Gong, Yaoqin, Wang, Molin
Format: Artigo
Language:Inglês
Published: e-Century Publishing Corporation 2015
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396031/
https://ncbi.nlm.nih.gov/pubmed/25973295
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items